Ad
BIIB Quote Trading Chart Biogen Inc.
home / stock / biib / biib quote
$267 Last:
-0.47% Change Percent:
$265.51 Open:
$267 Previous Close:
$271.49 High:
$257.0201 Low:
3,745,849 Volume:
12/31/1969 07:00:00 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
BIIB Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2022-09-30 | 265.51 | 267 | 271.49 | 257.0201 | 3,745,849 |
| 2022-09-29 | 269.29 | 264.28 | 271.38 | 260.3602 | 6,183,961 |
| 2022-09-28 | 282.96 | 276.61 | 283.44 | 265.02 | 16,232,041 |
| 2022-09-27 | 197.02 | 197.79 | 200.95 | 195.4984 | 849,168 |
| 2022-09-26 | 197.44 | 195.75 | 199.805 | 194.63 | 1,021,416 |
| 2022-09-23 | 200.28 | 197.78 | 200.62 | 194.45 | 1,443,578 |
| 2022-09-22 | 197.49 | 200.62 | 201.675 | 195.58 | 712,032 |
| 2022-09-21 | 205.53 | 199.34 | 209.25 | 199.295 | 1,068,567 |
| 2022-09-20 | 207.78 | 204.2 | 207.95 | 202.65 | 947,131 |
| 2022-09-19 | 206.88 | 209.26 | 210.18 | 205.5316 | 843,912 |
| 2022-09-16 | 206.54 | 208.26 | 209.19 | 204.23 | 1,904,404 |
| 2022-09-15 | 203.32 | 206.72 | 208.71 | 202.64 | 1,021,658 |
| 2022-09-14 | 204.9 | 204.11 | 205.065 | 200.745 | 840,885 |
| 2022-09-13 | 208.9 | 203.91 | 209.9672 | 203.29 | 1,064,214 |
| 2022-09-12 | 212.1 | 212.88 | 216.17 | 211.08 | 955,638 |
| 2022-09-09 | 208.39 | 211.84 | 212.92 | 208.09 | 1,053,076 |
| 2022-09-08 | 201.16 | 207.98 | 208.05 | 201.16 | 1,039,172 |
| 2022-09-07 | 195.42 | 200.67 | 201.25 | 194.45 | 766,232 |
| 2022-09-06 | 196.06 | 194.69 | 198 | 194.42 | 766,495 |
| 2022-09-02 | 201.71 | 196.03 | 201.71 | 194.705 | 762,094 |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
Shares of Biogen (NASDAQ: BIIB) shot up as much as 37.1% this week, according to data from S&P Global Market Intelligence . The large-cap drugmaker with a market cap of $39 billion announced that its new Alzheimer's drug it developed in a partnership with Eisai showed tr...
-
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB800, a biosimilar candidate referencing RoACTEMRA ®1 (tocilizumab), an anti-inte...
-
Tens of millions of Alzheimer's disease patients were given a rare dose of good news recently when Biogen (NASDAQ: BIIB) released some encouraging clinical trial results for its new Alzheimer's disease treatment candidate. The data from a big pivotal trial of that experimental treat...